Session » Metabolic and Crystal Arthropathies Poster I

Date: Monday, November 6, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1142

A Case Control Study of Anakinra Use for Acute Gout in a VA Patient Cohort Reveals Association with East Asian Descent, High Urate Burden, and Increased Co-Morbidities and All-Cause Mortality

9:00AM-11:00AM: Abstract Number: 1134

A Case Series of Gout and Downs Syndrome – a New Paradigm for Detecting Disease Associations Using Big Data

9:00AM-11:00AM: Abstract Number: 1104

A Genome-Wide Association Study of Gout in People of European Ancestry

9:00AM-11:00AM: Abstract Number: 1105

Allopurinol Dose Escalation to Achieve Serum Urate below 6mg/Dl: An Open Label Extension Study

9:00AM-11:00AM: Abstract Number: 1121

Allopurinol Treatment for Gout: How Long to Reach Serum Urate Goal?

9:00AM-11:00AM: Abstract Number: 1107

An Illness By Any Other Name: The Effect of Changing the Disease Label of Gout on the Perceptions of the Illness and Its Management

9:00AM-11:00AM: Abstract Number: 1133

Are We Ready? Changes in the Profile of Gout Patients over the Last 25 Years

9:00AM-11:00AM: Abstract Number: 1106

Association between ABCG2 rs2231142 and Poor Response to Allopurinol: Replication and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1130

Can Alcohol Intake in Moderation Lower the Risk of Myocardial Infarction and Mortality Even Among Gout Patients?

9:00AM-11:00AM: Abstract Number: 1110

Clinical Features and Risk of Recurrent Attack in Gout Patients According to Serum Urate Levels during an Acute Gout Attack

9:00AM-11:00AM: Abstract Number: 1132

Compensated Polarized Microscopy for Crystal Identification Shows High Reliability Among Multiple Observers

9:00AM-11:00AM: Abstract Number: 1118

Diabetes and Gout: Real-World Evidence Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization

9:00AM-11:00AM: Abstract Number: 1108

Effect of Body Mass Index on Serum Urate and Renal Uric Acid Handling Responses to an Oral Inosine Load

9:00AM-11:00AM: Abstract Number: 1128

Effect of Urate-Lowering Treatment on the Risk of Urolithiasis in People with Gout

9:00AM-11:00AM: Abstract Number: 1114

Effects of Diacerein Controlled Release Tablets in Serum Uric Acid Reduction in Treating Subjects with Gout

9:00AM-11:00AM: Abstract Number: 1112

Efficacy of High Dose Versus Moderate Dose Prednisone in the Treatment of Acute Gout

9:00AM-11:00AM: Abstract Number: 1125

Factors Associated with Acute Gouty Arthritis in Patients Hospitalized with Acute Coronary Syndromes and Congestive Heart Failure

9:00AM-11:00AM: Abstract Number: 1140

Gout Characteristics and Its Association with the Presence of Cardiovascular Disease: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 1126

High Osteoprotegerin:RANKL Ratios in Synovial Fluid Correlate with the Presence of Calcium Pyrophosphate Crystals

9:00AM-11:00AM: Abstract Number: 1129

Impact of Diuretics on Urate Lowering Therapy in Patients with Gout: Analysis of an Inception Cohort

9:00AM-11:00AM: Abstract Number: 1141

Initial Results of a Clinical Study to Determine Whether a Tolerizing Regimen of Pegloticase Can Increase the Frequency of Subjects Having Sustained Lowering of Serum Urate

9:00AM-11:00AM: Abstract Number: 1144

Initiating Colchicine and Urate-Lowering Therapy Reduces Baseline Inflammation, and Improves Vascular Endothelial but Not Smooth Muscle Function in Gout Subjects: Resistance to Endothelial Improvement Among Patients with Cardiovascular Comorbidities

9:00AM-11:00AM: Abstract Number: 1138

Investigation on Allele Frequency of Rs3117583 and Rs9263726 in Patients with Hyperuricemia or Gout

9:00AM-11:00AM: Abstract Number: 1120

Less Than Half of Patients Treated with High-Dose Allopurinol Reach Serum Uric Acid Target

9:00AM-11:00AM: Abstract Number: 1115

Long-Term Adherence to Urate-Lowering Therapy in Gout: Do Not Blame on the Patients

9:00AM-11:00AM: Abstract Number: 1116

Management of Acute Gout in Hospitalized Patients and Risk Factors for Xanthine Oxidase Inhibitor (XOI) Discontinuation or Dose Reduction

9:00AM-11:00AM: Abstract Number: 1139

Management of Gout – a Survey for Healthcare Providers in South Australia

9:00AM-11:00AM: Abstract Number: 1124

Marked Variability of Circulating Urate Concentrations in Banked Samples Based on Sample Type and Assay

9:00AM-11:00AM: Abstract Number: 1122

Prevalence of Chronic Kidney Disease and Uncontrolled Serum Uric Acid Levels in US Adult Gout Population: Results from the National Health and Nutrition Examination Survey 2007–2012

9:00AM-11:00AM: Abstract Number: 1111

Protective Effect of Allopurinol Use on Kidney Function Among Patients with Gout and Chronic Kidney Disease

9:00AM-11:00AM: Abstract Number: 1123

Random Urinary Uric Acid/Creatinine Ratio Is Useful in the Estimation of 24-Hour Urine Uric Acid Excretion in Patients with Gout

9:00AM-11:00AM: Abstract Number: 1127

Replication of Genetic Association of Peroxisome Proliferator-Activated Receptor Gamma-1B with Gout in a New Zealand Polynesian Sample Set

9:00AM-11:00AM: Abstract Number: 1113

Risk of Cardiovascular Events in Older Patients with Gout Initiating Probenecid Versus Allopurinol: A Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 1109

Sex Differences in Gout Patients: Epidemiology, Flares and Hospitalization Data in a Population Based Cohort

9:00AM-11:00AM: Abstract Number: 1117

the Absolute Risk of Clinically Diagnosed Gout By Serum Uric Acid Levels – Results from 30 Years Follow-up of the Malmö Preventive Project Cohort in Southern Sweden

9:00AM-11:00AM: Abstract Number: 1131

The Dietary Approaches to Stop Hypertension (DASH) and Mediterranean Diets and Risk of Gout in Women: 28-Year Follow-up of a Prospective Cohort

9:00AM-11:00AM: Abstract Number: 1135

the Incidence of Knee Chondrocalcinosis and Its Risk Factors in Community-Based Cohort

9:00AM-11:00AM: Abstract Number: 1143

The Patient Education for Gout Patients Ameliorate the Patients’ Satisfaction and Serum Uric Acid Level

9:00AM-11:00AM: Abstract Number: 1119

Uncontrolled Gout Patients with Higher Heart Failure Hospitalization Rates in US

9:00AM-11:00AM: Abstract Number: 1137

Urate Lowering to ACR-Recommended Targets Allows Significant Improvement of Severe Gout: A Monocentric Prospective Trial in Vietnam, Using a Systematic Treatment Protocol

9:00AM-11:00AM: Abstract Number: 1136

Urate-Lowering Treatment and Risk of Total Joint Replacement in Patients with Incident Gout: A Population-Based Cohort and Nested Case-Control Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].